Diagnostic value of 18F-fluordesoxyglucose ...
Document type :
Compte-rendu et recension critique d'ouvrage
PMID :
Title :
Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Author(s) :
Wolpert, Fabian [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Weller, Michael [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Berghoff, Anna Sophie [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Rushing, Elisabeth [Auteur]
University hospital of Zurich [Zurich]
Füreder, Lisa Michaela [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Petyt, Gregory [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leske, Henning [Auteur]
University hospital of Zurich [Zurich]
Andratschke, Nicolaus [Auteur]
University hospital of Zurich [Zurich]
Regli, Luca [Auteur]
University hospital of Zurich [Zurich]
Neidert, Marian Christoph [Auteur]
University hospital of Zurich [Zurich]
Stupp, Roger [Auteur]
University hospital of Zurich [Zurich]
Stahel, Rolf [Auteur]
University hospital of Zurich [Zurich]
Dummer, Reinhard [Auteur]
University hospital of Zurich [Zurich]
Frauenfelder, Thomas [Auteur]
University hospital of Zurich [Zurich]
Roth, Patrick [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Reyns, Nicolas [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Kaufmann, Philipp Antonio [Auteur]
University hospital of Zurich [Zurich]
Preusser, Matthias [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Le Rhun, Emilie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
University hospital of Zurich [Zurich]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Weller, Michael [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Berghoff, Anna Sophie [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Rushing, Elisabeth [Auteur]
University hospital of Zurich [Zurich]
Füreder, Lisa Michaela [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Petyt, Gregory [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leske, Henning [Auteur]
University hospital of Zurich [Zurich]
Andratschke, Nicolaus [Auteur]
University hospital of Zurich [Zurich]
Regli, Luca [Auteur]
University hospital of Zurich [Zurich]
Neidert, Marian Christoph [Auteur]
University hospital of Zurich [Zurich]
Stupp, Roger [Auteur]
University hospital of Zurich [Zurich]
Stahel, Rolf [Auteur]
University hospital of Zurich [Zurich]
Dummer, Reinhard [Auteur]
University hospital of Zurich [Zurich]
Frauenfelder, Thomas [Auteur]
University hospital of Zurich [Zurich]
Roth, Patrick [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
University hospital of Zurich [Zurich]
Reyns, Nicolas [Auteur]

Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Kaufmann, Philipp Antonio [Auteur]
University hospital of Zurich [Zurich]
Preusser, Matthias [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Le Rhun, Emilie [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
University hospital of Zurich [Zurich]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Journal title :
European Journal of Cancer
Pages :
64-72
Publisher :
Elsevier
Publication date :
2018-06
ISSN :
0959-8049
English keyword(s) :
Brain metastasis
CUPS
FDG-PET/CT
GPA
CUPS
FDG-PET/CT
GPA
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background: In 30% of patients with brain metastasis (BM), neurological symptoms are the first clinical manifestation of systemic malignancy, referred to as BM from cancer of unknown primary site (BM-CUPS). Here, we define ...
Show more >Background: In 30% of patients with brain metastasis (BM), neurological symptoms are the first clinical manifestation of systemic malignancy, referred to as BM from cancer of unknown primary site (BM-CUPS). Here, we define the diagnostic value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the workup of BM-CUPS.Methods: We screened 565 patients operated for BM at the University Hospital Zurich and identified 64 patients with BM-CUPS with data on both FDG-PET/CT and contrast-enhanced chest/abdomen computed tomography (CT) available at BM diagnosis. A cohort of 125 patients with BM-CUPS from Lille and Vienna was used for validation.Results: FDG-PET/CT was not superior to chest/abdomen CT in localising the primary lesion in the discovery cohort, presumably because most primary tumours were lung cancers. However, FDG-PET/CT identified additional lesions suspicious of extracranial metastases in 27 of 64 patients (42%). The inclusion of FDG-PET/CT findings shifted the graded prognostic assessment (GPA) score from 3 with CT alone to 2.5 for PET/CT (p = 3.8 × 10-5, Wilcoxon's test), resulting in a predicted survival of 5.3 versus 3.8 months (p = 6.1 × 10-5; Wilcoxon's test). All observations were confirmed in the validation cohort.Conclusions: Lung cancers are the most common primary tumour in BM-CUPS; accordingly, CT alone shows similar overall sensitivity for detecting the primary tumour as FDG-PET/CT. Yet, FDG-PET/CT improves the accuracy of staging by detecting more metastases, reflected by decreased GPA scores and decreased predicted survival. Therefore, randomised trials on patients with BM should standardise methods of staging, notably when stratifying for GPA.Show less >
Show more >Background: In 30% of patients with brain metastasis (BM), neurological symptoms are the first clinical manifestation of systemic malignancy, referred to as BM from cancer of unknown primary site (BM-CUPS). Here, we define the diagnostic value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the workup of BM-CUPS.Methods: We screened 565 patients operated for BM at the University Hospital Zurich and identified 64 patients with BM-CUPS with data on both FDG-PET/CT and contrast-enhanced chest/abdomen computed tomography (CT) available at BM diagnosis. A cohort of 125 patients with BM-CUPS from Lille and Vienna was used for validation.Results: FDG-PET/CT was not superior to chest/abdomen CT in localising the primary lesion in the discovery cohort, presumably because most primary tumours were lung cancers. However, FDG-PET/CT identified additional lesions suspicious of extracranial metastases in 27 of 64 patients (42%). The inclusion of FDG-PET/CT findings shifted the graded prognostic assessment (GPA) score from 3 with CT alone to 2.5 for PET/CT (p = 3.8 × 10-5, Wilcoxon's test), resulting in a predicted survival of 5.3 versus 3.8 months (p = 6.1 × 10-5; Wilcoxon's test). All observations were confirmed in the validation cohort.Conclusions: Lung cancers are the most common primary tumour in BM-CUPS; accordingly, CT alone shows similar overall sensitivity for detecting the primary tumour as FDG-PET/CT. Yet, FDG-PET/CT improves the accuracy of staging by detecting more metastases, reflected by decreased GPA scores and decreased predicted survival. Therefore, randomised trials on patients with BM should standardise methods of staging, notably when stratifying for GPA.Show less >
Language :
Anglais
Popular science :
Non
Source :